Stockwinners Market Radar for November 06, 2018 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

21:06 EDT Sun Communities makes strategic $54M investment in Ingenia Communities - Sun Communities announced a strategic investment in Ingenia Communities Group, a leading owner, operator and developer of senior manufactured housing communities and holiday resorts in Australia, as well as a development joint venture with Ingenia. Sun will invest approximately $54 million for a 9.9% ownership stake in Ingenia. Sun and Ingenia will also form a 50/50 joint venture to establish and grow a manufactured housing community development program in Australia.

19:29 EDT National Oilwell announces $500M stock repurchase program

19:16 EDT SSR Mining provides November exploration update - SSR Mining provided an update on its exploration activities and results at its Marigold mine in Nevada, U.S., and Seabee Gold Operation in Saskatchewan, Canada for the period from August 1, 2017 to September 30, 2018. At the Seabee Gold Operation, confirmation of a discovery at the Santoy Gap hanging wall is expected to define new gold Mineral Resources when we report our Mineral Resources and Mineral Reserves estimates for year-end 2018. Drill results at Santoy Gap HW include: Drillhole SUG-18-622 intersected 25.6 g/t gold over 4.1 meters true width; and Drillhole SUG-18-612 intersected 12.3 g/t gold over 4.8 meters true width. Also at the Seabee Gold Operation, infill drilling at Santoy 8A is expected to convert Inferred Mineral Resources to the Indicated category when we report our Mineral Resources and Mineral Reserves estimates for year-end 2018. Drill results at Santoy 8A include: Drillhole SUG-18-941 intersected 11.2 g/t gold over 18.5 meters true width; and Drillhole SUG-18-943 intersected 14.1 g/t gold over 7.0 meters true width; and Drillhole SUG-18-913 intersected 12.2 g/t gold over 7.0 meters true width. Infill drill results for the Red Dot area at the Marigold mine include: Drillhole MRA6626 intersected 3.4 g/t gold over 71.6 meters intersected width, including 8.9 g/t gold over 25.9 meters intersected width; and Drillhole MRA6647 intersected 1.2 g/t gold over 185.9 meters intersected width, including two higher grade intervals of 8.8 g/t gold over 6.1 meters, and 3.6 g/t gold over 32.0 meters.

18:10 EDT Alliant Energy raises annual dividend 6% to $1.42 - Alliant Energy's Board of Directors approved a 6% increase, or 8c per share, to its 2019 expected annual common stock dividend target of $1.42 per share from the current annual common stock dividend target of $1.34 per share.

17:57 EDT McDermott chairman, CFO, CEO acquire company shares - McDermott International announced purchases by its chairman and executive management of the company's common stock. Gary Luquette, non-executive chairman of the board of directors, purchased approximately $500,000 of McDermott stock, bringing his total shares owned to 90,250. David Dickson, president and CEO, purchased approximately $400,000 of McDermott stock, bringing his total shares owned to 459,889. Stuart Spence, executive VP and CFO, purchased approximately $250,000 of the company's stock, bringing his total shares owned to 141,961.

17:50 EDT Eagle Bulk Shipping reports Q3 adjusted EBITDA $20.2M, up 140% from last year - Achieved a time charter equivalent, or TCE, of $11.8K for the quarter, an increase of 30% from last year.

17:47 EDT Xcel Energy to buy Mankato Energy Center for $650M - Xcel Energy announced it has agreed to purchase the Mankato Energy Center, a 760-megawatt natural gas power plant from Southern Power, a subsidiary of Atlanta-based Southern Company. The plant currently provides power to Xcel Energy customers under a power purchase contract. Xcel Energy is planning for several power plant retirements and contract expirations in the mid-2020s. Acquiring this plant now provides certainty that energy from these newer generating units will be available and benefit customers over the life of the plant compared to simply purchasing the output. These benefits include more flexibility as we continue to add renewable energy and analyze the future of our always-on power plants, as well as reducing the risk from expiring power purchase agreements in the next decade. Xcel Energy has purchased power from the plant's first unit since 2006 and has an agreement for the energy from the under-construction second unit beginning in 2019. Xcel Energy agreed to purchase the plant for $650 million. Current employees will be offered jobs with Xcel Energy.

17:32 EDT OMA Airports reports October passenger traffic up 10.7% from last year - Grupo Aeroportuario del Centro Norte, known as OMA, reports that terminal passenger traffic at its 13 airports increased 10.7% in October 2018, as compared to October 2017. Domestic traffic increased 11.5%, and international traffic increased 4.1%.

17:27 EDT Akorn says can't predict timing of Fresenius appeal decision - The company said in tonight's earnings release, "What are Akorn's expectations for the appeal of the Delaware Court of Chancery ruling? We believe in the merit of our appeal, but the ultimate decision is up to the Supreme Court of the State of Delaware, which will hear oral arguments on December 5, 2018. We cannot predict the timing of the decision, however, we were pleased that the Court granted our Motion to Expedite. What happens if Akorn loses the appeal? When will you give guidance? It is premature to communicate any forward-looking guidance; we appreciate your patience as we work through the appeal process. If we do not prevail, we will continue our focus on creating long-term shareholder value and advancing our mission to improve patients' lives through the quality, availability and affordability of our products. What's the value proposition for shareholders now? Akorn has a long history of creating shareholder value through the manufacture and marketing of generic and branded prescription pharmaceuticals, as well as animal and consumer health products. We specialize in difficult-to-manufacture sterile and non-sterile dosage forms including ophthalmics, injectables, oral liquids, otics, topicals, inhalants and nasal sprays. While the ongoing litigation has created distractions and included many misleading and false allegations about Akorn, our commitment to running the business, complying with regulatory requirements and pursuing avenues for growth has not changed."

17:25 EDT Akorn received Form 483 after FDA inspection ending in August - The company said in tonight's earnings release, "Our Decatur facility received a Form 483 at the conclusion of an FDA inspection in May 2018, to which we submitted a robust response in early June. We have made substantial progress (approximately 80% of our action items are complete) and we are on track to complete the majority of the remaining action items by the end of 2018. Our Somerset facility received a Form 483 following an FDA inspection ending in August 2018, to which we submitted a robust response in late September. We are on schedule with our action items and have made good progress already with approximately 45% of our action items completed."

17:24 EDT Akorn attributes revenue decline to competition on key products - Akorn said, "Revenues declined predominantly due to the effect of competition on key products such as Ephedrine Sulfate Injection, Lidocaine Ointment, Methylene Blue Injection and Nembutal; In the third quarter of 2018, the decrease in revenues due to pricing was approximately 3% compared to the same period in 2017, the lowest drop in the trailing six quarters."

17:10 EDT Triumph secures contract for G500/G600 fuselage frames - Triumph Group announced that its Aerospace Structures business has been selected by Gulfstream to manufacture a new order of fuselage frames for the Gulfstream G500 and Gulfstream G600 aircraft. Under terms of the agreement, which will run through 2020, Triumph Fabrications in Hot Springs, Arkansas will produce the fuselage frames with stretch formed extrusions that will then be machined into final configurations.

17:05 EDT Mitek Systems names Max Carnecchia CEO - Mitek Systems announced that Max Carnecchia has been named Chief Executive Officer and appointed to the company's Board of Directors, effective immediately.

17:04 EDT CM7Star to combine with Renren's Kaixin in all-stock transaction valued at $454M - CM Seven Star Acquisition Corporation (CMSS) and Kaixin Auto Group, a leading premium used car dealership network in China and its owner, Renren (RENN), announced that each company's board has unanimously approved a definitive share exchange agreement. Pursuant to this agreement, CM7Star will acquire 100% of the issued and outstanding shares of Kaixin in a transaction valued at approximately $454M. Kaixin's corporate parent will sell 100% of Kaixin's equity holdings to CM7Star in exchange for an initial consideration of approximately 28.3 million CM7Star shares, subject to certain indemnification arrangements. All amounts remaining in CM7Star's trust account at the closing of the business combination is expected to be used for Kaixin's growth.

17:03 EDT Belmond backs FY18 same store RevPAR growth view 2%-6% - Backs FY18 adjusted EBITDA view of $140M-$150M.

17:00 EDT Valero General Counsel Jay Browning to retire, to be replaced by Jason Fraser - Valero Energy Corporation announced that Jay Browning has decided to retire as the company's executive VP and General Counsel effective January 1, 2019. Valero's board has elected Jason Fraser, currently senior VP & Counsel, Public Policy, Strategy, and External Communications, as executive VP and General Counsel effective the same date.

16:55 EDT Playa Hotels & Resorts sees FY18 EBITDA $175M-177M - FY18 EBITDAPlaya Hotels & Resorts is lowering the mid-point of its full year 2018 EBITDA guidance by $1.5 million and establishing a revised range of $175.0 to $177.0 million in light of the unanticipated spike in utilities. Achievement of the anticipated results is subject to the risks disclosed in the Company's filings with the U.S. Securities and Exchange Commission.

16:53 EDT Callon Petroleum sees FY18 total production MBOE/d 32.0-33.0

16:52 EDT Wendy's reports Q3 North America SSS down 0.2% - Q3 adjusted EBITDA $107.2M vs. $97.6M last year.

16:47 EDT Momenta settles with AbbVie regarding commercializing M923 - Momenta Pharmaceuticals (MNTA) announced that it has executed agreements with AbbVie (ABBV) providing license rights for the global launch of M923, Momenta's proposed biosimilar to Humira. Under the terms of the agreements and subject to approval by health regulatory authorities, Momenta may launch M923 in the United States on November 20, 2023 and in Europe upon approval by the European Medicines Agency. Momenta plans to submit a biologics license application for M923 to the FDA in Q4 of 2018 and a marketing authorization application in the European Union in the first half of 2019.

16:46 EDT W&T Offshore announces senior management changes - W&T Offshore announced certain executive management changes within the company, effective immediately. The company announced the appointment of Janet Yang to Executive Vice President and CFO, following her appointment as acting CFO in August 2018. Yang will also assume the role of Principal Accounting Officer of the company. Additionally, the company announced the promotions of David Bump from Vice President to Executive Vice President, Drilling, Completions and Facilities and William Williford from Vice President to Executive Vice President and General Manager of Gulf of Mexico. The company also announced the departure of Thomas Murphy, Senior Vice President and COO. Bump and Williford will be assuming the duties of Murphy.

16:41 EDT API crude inventories for week of November 2 - API reports that crude inventories rose 7.83M barrels last week. Gasoline inventories fell 1.2M barrels, according to Bloomberg, citing people familiar with the data. API's Weekly Statistical Bulletin is scheduled for release every Tuesday afternoon.

16:40 EDT Reading confirms receipt of indication of interest from Patton Vision - Reading Internationa lconfirmed that it has received an unsolicited, conditional indication of interest from Patton Vision, LLC, a holding company claiming to represent a consortium of investors, to acquire all of the outstanding shares of Reading Class A common stock for $17.22 per share in cash and Class B common stock for $37.38 per share in cash. As previously disclosed, the Company received correspondence from Patton Vision in December 2016 in which Patton Vision made an unsolicited, non-binding indication of interest to acquire all outstanding shares of Reading Class A and Class B common stock for $18.50 per share in cash. In addition, the Company received correspondence in May 2016 and September 2016, in which Patton Vision made unsolicited, non-binding indications of interest to acquire all of outstanding shares of Reading Class A and Class B common stock for $17.00 per share. The Board of Directors of Reading, in consultation with outside advisors, carefully evaluated these prior indications of interest. Following this review, the Board of Directors determined that the Company's stockholders would be better served by pursuing our independent, stand-alone strategic business plan and communicated this to Patton Vision. The Reading Board of Directors remains committed to acting in the best interest of all Reading stockholders and will review the revised unsolicited, conditional indication of interest in due course.

16:38 EDT Darling Ingredients raises share repurchase program for up to $200M from $100M - The Darling Ingredients Board also approved an increase in the company's previously announced share repurchase program from $100M to $200M and extended the term of the program for an additional year to August 13, 2020, to be exercised depending on market conditions.

16:35 EDT Match Group announces $2.00 per share special cash dividend - Match Group announced that its board has declared a special cash dividend of $2.00 per share on Match Group common stock and Class B common stock, payable on December 19, to stockholders of record as of the close of business on December 5. The special dividend will be funded with cash on hand and incremental debt, as necessary.

16:35 EDT Bristol-Myers says FDA approves Empliciti plus pomalidomide and dexamethasone - Bristol-Myers Squibb announced that the U.S. Food and Drug Administration approved Empliciti injection for intravenous use in combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor. In ELOQUENT-3, a randomized, open-label, Phase 2 trial, EPd demonstrated benefit in patients with relapsed or refractory multiple myeloma, doubling both median progression-free survival and overall response rate versus pomalidomide and dexamethasone.

16:35 EDT Zillow trading resumes

16:32 EDT BWX Technologies backs long-term CAGR view low-double digits - BWXT reiterated long-term guidance that, beyond 2017, and excluding the benefit of tax reform, the Company anticipates an EPS Compound Annual Growth Rate in the low-double digits over a three to five year period based on a robust organic growth strategy and balance sheet capacity.

16:32 EDT Victory Capital acquires USAA Asset Management Company - Victory Capital Holdings announced that it has entered into a definitive purchase agreement to acquire USAA Asset Management Company. USAA Asset Management Company, based in San Antonio, Texas, was formed to serve the investment needs of the military community and their families. As of September 30, USAA Asset Management Company had $69.2B in assets under management and 53 investment funds.

16:28 EDT Pioneer Natural sees Q4 Permian Basin oil production 188-194 MBOPD - Permian Basin oil production is forecasted to average between 188 MBOPD to 194 MBOPD. Permian Basin production is forecasted to average between 293 MBOEPD to 303 MBOEPD. Production costs are expected to average $9.00 per BOE to $11.00 per BOE. DD&A expense is expected to average $13.00 per BOE to $15.00 per BOE. Exploration and abandonment expense is forecasted to be $20 million to $30 million. General and administrative expense is expected to be $95 million to $100 million. Interest expense is expected to be $30 million to $35 million. Other expense is forecasted to be $50 million to $60 million and is expected to include $40 million to $45 million of charges associated with excess firm gathering and transportation commitments primarily related to the Eagle Ford asset. Accretion of discount on asset retirement obligations is expected to be $3 million to $6 million. The Company's effective income tax rate is expected to range from 21% to 25%. Current income taxes are expected to be less than $5 million.

16:27 EDT CenturyLink names Neel Dev as CFO, effective immediately - CenturyLink announced that Neel Dev has been named executive vice president and CFO, effective immediately. Dev, who has served as interim CFO since Sunit Patel's departure from the company in September, will have global responsibility for CenturyLink's financial planning, accounting, tax, treasury, procurement and supply chain management and real estate portfolio. Dev previously served as CenturyLink's group vice president of finance and was with Level 3 for 13 years prior to the CenturyLink acquisition. He has more than 20 years of experience in the telecommunications industry in both financial and operational roles.

16:24 EDT Kraft Heinz to sell natural cheese business to Parmalat for about $1.23B - The Kraft Heinz Company announced that it has entered into a definitive agreement to sell its Canadian natural cheese business to Parmalat for a purchase price of C$1.62B, or approximately $1.23Bat current FX rates. The agreement includes the sale of natural cheese brands Cracker Barrel, P'tit Quebec and aMOOza! in the Canadian market. The proposed transaction is expected to close in the first half of 2019, subject to regulatory review and approval. Under the terms of the agreement, Kraft Heinz will sell its production facility located in Ingleside, Ontario. Kraft Heinz Canada will also transfer approximately 400 employees from that facility to Parmalat. Kraft Heinz will continue to own and market its other cheese products, including Philadelphia, Cheez Whiz and Kraft Singles, which are processed in Mount Royal, Quebec, where Kraft Heinz Canada employs approximately 900 employees. The Kraft Heinz Company remains steadfast in its commitment to the Canadian market, illustrated by its recent acquisition of the Vancouver-based Ethical Bean coffee brand. Across Canada, Kraft Heinz currently employs approximately 2,000 employees in its facilities and thousands more, indirectly, through its co-manufacturers. The natural cheese business being sold contributed approximately C$560M to Kraft Heinz's net sales in 2017. Kraft Heinz expects to use transaction proceeds primarily to pay down debt, with reduced interest expenses expected to offset the majority of EPS dilution on a run-rate basis.

16:22 EDT Plains All American sees FY18 adjusted EBITDA $2.55B

16:19 EDT iPic Entertainment announces departure of CFO Paul Westra - iPic Entertainment announced that Paul Westra is resigning to rejoin the financial services industry. Andre Loehrer, iPic's Controller, will assume the position of interim CFO. The company has also commenced a formal search through Spencer Stuart for a new permanent CFO.

16:17 EDT Zillow names Allen Parker as CFO - Zillow Group (Z, ZG) announced Allen Parker will join the company as CFO. Parker will oversee the finance, treasury, accounting, M&A, legal and investor relations functions for Zillow Group. He will report to Zillow Group CEO, Spencer Rascoff. Parker brings nearly 30 years of experience in deep operational finance, including at Fortune 500 companies Amazon (AMZN) and General Electric (GE). Parker spent the last 13 years in finance roles at Amazon.

16:16 EDT Diamondback Energy increases FY18 production view to 118.5-119.5 Mboe/d

16:15 EDT Etsy up 11% in afterhours trading following earnings report

16:14 EDT GoDaddy authorizes $500M share repurchase - GoDaddy announces that its board of directors has approved the repurchase of up to $500M of the company's Class A common stock. GoDaddy may purchase shares from time to time in open market purchases, block transactions and privately negotiated transactions, in accordance with applicable federal securities laws. The program has no time limit and may be modified, suspended or terminated by the company at any time without prior notice.

16:13 EDT Intermolecular announces $10M share repurchase program - The board of directors of Intermolecular has approved a share repurchase program pursuant to which Intermolecular may repurchase up to $10M of shares of its common stock.

16:11 EDT Aclaris Therapeutics sees FY18 R&D expenses $62M -$64M - Aclaris has updated its expected 2018 GAAP R&D expenses to be in the range of $62 to $64 million, including estimated stock-based compensation of $7 million. Aclaris updated its expected 2018 GAAP selling, general and administrative expenses, which combine its Sales and marketing and General and administrative line items, to be in the range of $77 to $79 million, including estimated stock-based compensation of $14 million.

16:09 EDT SilverBow Resources sees Q4 production 203-2033 MMcfe/d

16:07 EDT Devon says light-oil production growth on track for 17% in 2018 - The company said, "With the strong well productivity Devon has achieved year to date in the U.S., light-oil production growth from retained assets is on track to advance 17 percent in 2018. This growth rate is trending at approximately 200 basis points above the company's original budget expectations, adjusted for asset sales."

16:06 EDT Bluegreen Vacations announces retirement of COO David Pontius - Bluegreen Vacations announced that David Pontius will be retiring as Executive Vice President and Chief Operating Officer in December 2018. Mr. Pontius has been with Bluegreen Vacations for over 11 years and has held several positions starting as President of Bluegreen's Resorts Division in 2007, Chief Strategy Officer in 2010 and a promotion to Chief Operating Officer in 2017.

16:01 EDT Zillow trading halted, news pending

16:00 EDT Infinera trading halted, news pending

15:26 EDT U.S. Physical Therapy CFO Lawrance McAfee sells over 3K shares of company stock - U.S. Physical Therapy CFO Lawrance McAfee disclosed in a filing that he had sold 3,100 shares of company stock at an average price of $113.29 per share on November 2. The total transaction value of the sale was $351,199.

13:18 EDT Medtronic says new data reinforce IN.PACT Admiral as 'durable, frontline option' - Medtronic said data presented in two late-breaking clinical trial presentations at the Vascular Interventional Advances 2018 conference reinforce the durability, safety, and effectiveness of the IN.PACT Admiral drug-coated balloon in patients with peripheral artery disease in the superficial femoral and popliteal arteries. "Since the entrance of DCBs into the market several years ago, we have seen a shift towards the use of this technology as a frontline therapy to treat patients with PAD. This is especially true of IN.PACT Admiral DCB, which has consistently proven to be one of the safest, most effective, and durable therapies in treating patients across the spectrum of femoral-popliteal disease. We are proud to have become the first company to share five-year data on a commercially-available DCB and the first to present outcomes from the largest pooled analysis in the peripheral space to-date. We believe this new evidence will give physicians the confidence that IN.PACT Admiral DCB is the preferred first line therapy for patients who suffer with femoral-popliteal disease," said Mark Pacyna, vice president and general manager of the Peripheral business in the Medtronic Cardiac & Vascular Group. "

13:03 EDT AMD unveils 'world's first' 7nm datacenter GPUs - AMD announced the AMD Radeon Instinct MI60 and MI50 accelerators, the world's first 7nm datacenter GPUs, designed to deliver the compute performance required for next-generation deep learning, HPC, cloud computing and rendering applications. Researchers, scientists and developers will use AMD Radeon Instinct accelerators to solve tough and interesting challenges, including large-scale simulations, climate change, computational biology, disease prevention and more. "Legacy GPU architectures limit IT managers from effectively addressing the constantly evolving demands of processing and analyzing huge datasets for modern cloud datacenter workloads," said David Wang, senior vice president of engineering, Radeon Technologies Group at AMD. "Combining world-class performance and a flexible architecture with a robust software platform and the industry's leading-edge ROCm open software ecosystem, the new AMD Radeon Instinct(TM) accelerators provide the critical components needed to solve the most difficult cloud computing challenges today and into the future."

12:57 EDT Myomo announces receipt of two Medicare codes - Myomo announces that the Centers for Medicare & Medicaid Services has published two new codes pursuant to the company's application for Healthcare Common Procedure Coding System "L" codes. Myomo had filed its application in December 2017 to have CMS establish two new Level II HCPCS codes and received a favorable preliminary decision in May. The codes cover MyoPro Motion E and W and MyoPro Motion G correspondingly. The codes become effective January 1, 2019. The assignment of unique L-codes, if followed by appropriate coverage and payment terms, would offer greater access to MyoPro for Medicare beneficiaries. Myomo Chief Medical Officer Dr. Brandon Green said, "The MyoPro has already helped so many patients with neurological/neuromuscular injury and illness by supporting their weakened arms, restoring control over their range of motion, reducing their healthcare costs, and giving them back their independence. It is important for clinically qualified Medicare and Medicaid beneficiaries to have access to this technology too."

12:39 EDT EU approves Disney's acquisition of Fox parts, subject to conditions - The European Commission has approved, under the EU Merger Regulation, the proposed acquisition of parts of Fox (FOXA) by Disney (DIS), both U.S. based global media companies. The decision is conditional on full compliance with commitments offered by Disney. The proposed transaction would combine Disney and parts of Fox, including its film and television studios and its cable and international television businesses. The Fox Broadcasting network and stations, Fox News Channel, Fox Business Network, FS1, FS2 and Big Ten Network are not part of the transaction. To address the Commission's competition concerns, Disney committed to divest its interest in all factual channels it controls in the EEA, namely: History, H2, Crime & Investigation, Blaze and Lifetime channels. These channels are currently controlled by A+E Television Networks, which is a joint venture between Disney and Hearst. The commitments fully remove the overlap between Disney's and Fox's activities in the wholesale supply of factual channels in the EEA. Therefore, the Commission concluded that the proposed transaction, as modified by the commitments, would no longer raise competition concerns. The Commission's decision is conditional upon full compliance with the commitments. Reference Link

12:28 EDT Occidental Petroleum sees FY18 total production 655-659 Mboed - Sees FY18 Permian resources production of 211-213 Mboed. Sees FY18 international production of 286-287 Mboed. Sees FY18 Domestic oil & gas production costs approximately $12.50/ boe. Sees FY18 exploration expense approximately 135M. Sees FY18 DD&A oil and gas approximately $13.50/boe. Sees FY18 DD&A chemical and midstream approximately $700M. Sees FY18 midstream pre-tax income $1.68B-$1.78B. Sees FY18 chemical segment pre-tax income approximately $1.16B.

12:18 EDT AMD announces EPYC processors now available on Amazon Web Services - AMD (AMD) and Amazon Web Services (AMZN) announced today at Next Horizon the immediate availability of the first AMD EPYC processor-based instances on Amazon Elastic Compute Cloud. The new instances are available as variants of Amazon EC2's memory optimized and general purpose instance families. AMD-based M5 and R5 instances are available in six sizes with up to 96 vCPUs, up to 768 GB of memory. AMD-based T3 instances will be available in 7 sizes with up to 8 vCPUs and 32 GB of memory. The new instances can be purchased as On-Demand, Reserved, or Spot instances. "The availability of multiple AMD EPYC processor-powered instances on Amazon EC2 instances marks a significant milestone in the growing adoption of our high-performance CPUs with cloud service providers," said Forrest Norrod, senior vice president and general manager, Datacenter and Embedded Solutions Business Group, AMD. Following the announcement, AMD shares are up 5.5% while Intel (INTC) has slid to be down about 1%.

12:16 EDT AMD announces EPYC processors now available on Amazon Web Services

12:08 EDT Elanco granted FDA approval for first animal drug that reduces gas emissions - The U.S. Food and Drug Administration announced the approval of Experior, which it identified as the first animal drug that when fed to beef cattle under specific conditions results in less ammonia gas released as a by-product of their waste. The FDA granted approval of Experior to Elanco.

12:04 EDT CUI Global unit Orbital in pact with Mitsubishi Electric Europe BV - CUI Global announced that its wholly-owned United Kingdom energy division, Orbital Gas Systems , has entered into a technical collaboration with Mitsubishi Electric Europe BV to further enhance Orbital's remote telemetry unit,RTU, and BioMethane product lines with Mitsubishi Electric's leading-edge automation control platforms. The partnership will ensure Orbital continues to utilize optimum industry standard equipment for its product lines. Mitsubishi Electric, a global leader in automation products, will provide the hardware product platform and technical support, with Orbital contributing system design and implementation expertise. Customers will benefit from the continuity of Mitsubishi Electric product support, diversity of implementation knowledge and speedy turnaround of hardware supply. Both companies will partner in the marketing and sales of the product lines. The services will initially benefit U.K. gas transmission and gas distribution networks with further collaboration expected throughout Europe and North America.

12:01 EDT AAC Holdings falls -32.9% - AAC Holdings is down -32.9%, or -$1.75 to $3.56.

12:00 EDT e.l.f. Beauty rises 16.5% - e.l.f. Beauty is up 16.5%, or $1.83 to $12.94.

12:00 EDT On Deck Capital rises 28.2% - On Deck Capital is up 28.2%, or $1.90 to $8.62.

11:44 EDT Euro Tech says 'caught attention' of marine service companies at trade show - In a post to its corporate blog, Euro Tech Holdings stated: "Seatrade Maritime Middle East 2018 at Dubai UAE attracted over 8000 attendees from more than 90 countries - including the industry's elite and most prominent personalities...We have shown our ET1302 Rapid Ballast Checker and co-exhibit with our sister company PACT China, who shown their ballast water system and port solutions. We caught attention of regional marine service companies and trading companies who are interested in working with us as business partners." Reference Link

11:32 EDT Keysight, Cohu extend collaboration to offer HVM testing of 5G power amplifiers - Keysight Technologies (KEYS) announced it has extended the company's collaboration with Cohu (COHU) to deliver enhanced high volume manufacturing solutions for the 5G semiconductor manufacturing test market. The integration of Keysight's 5G NR Signal Studio and PXI modular instruments with Cohu's HVM radio frequency test tools enables 5G semiconductor manufacturers to streamline the transition from device validation testing to HVM. Tightly integrated tools in both DVT and HVM allow users to easily correlate measurement test results, leading to faster time-to-volume of 5G power amplifiers and RF front-end modules.

11:28 EDT JPMorgan's Smith: Shadow banks could run into 'real issues' in consumer loans

11:25 EDT JPMorgan's Smith says pulled back from near-prime segment in credit cards - Says also pared risk on long-duration car loans.

11:20 EDT Symantec jumps 14% after private equity firm said to make takeover approach - Shares of Symantec have jumped after Reuters reported, citing people familiar with the matter, that technology-focused private equity firm Thoma Bravo has approached the cybersecurity software company about a potential deal to go private. Symantec previously reached a settlement with activist hedge fund Starboard Value in September and PE firms Bain Capital and Silver Lake are also investors, the report noted. In morning trading, Symantec shares are up $2.82, or 14%, to $22.84.

11:18 EDT JPMorgan's Smith says has had 'no problems at all' attracting talent

11:14 EDT Symantec trading halted, volatility trading pause

11:02 EDT JPMorgan's Smith says headcount at branches down about 14,000 from peak

10:53 EDT JPMorgan's Gordon Smith says economy looks 'really strong' - Gordon Smith, Co-President, & Co-COO, JPMorgan Chase & CEO, Consumer & Community Banking, told the Bank of America Merrill Lynch Future of Financials Conference that the economy looks "really strong."

10:25 EDT Marriott doesn't expect strikes to have 'material' impact on Q4 earnings - Says integrated Starwood and Marriott's loyalty programs. Says still addressing issues for some customers. Says new Enhanced Registration System has been rolled out to over 500 hotels. Says expects global RevPAR will increase 2% in Q4. Expects global RevPAR up 2%-3% in 2019. Expects North American RevPAR growth of 1% for Q4. Expects RevPAR in North America to increase 1%-3% in 2019. Says doesn't expect strikes to have a material impact on Q4 earnings. Expects Q4 Asia-Pacific RevPAR up MSD rate. Expects Q4 RevPAR in Europe to grow at MSD rate. Expects 2019 RevPAR to grow at a MSD rate. Expects Middle East & Africa RevPAR to decline at a LSD rate in Q4. Expects Middle East & Africa RevPAR to be "flattish" in 2019. Expects Q4 RevPAR in Caribbean & Latin America to increase at MSD rate. Expects net room growth of roughly 5% in 2018. Says does not see economic downturn on horizon. Expects gross fee revenues to total $900M-$910M in Q4. Expects net interest expense to total $90M in Q4. Expects to return roughly $3.7B to shareholders in 2018. Comments taken from Q3 earnings conference call.

10:09 EDT Morgan Stanley's Pick says prepping for possible hard Brexit

10:02 EDT Morgan Stanley's Pick says saw some de-risking by trading clients in October

10:00 EDT Fabrinet rises 18.6% - Fabrinet is up 18.6%, or $8.40 to $53.60.

09:59 EDT Morgan Stanley executive says October 'bumpy' for capital markets - Ted Pick, Head of Morgan Stanley's Institutional Securities Group, told the Bank of America Merrill Lynch Future of Financials Conference that October was "bumpy" for capital markets. He said "clearly, volatility had some impact on client behavior" in the sales and trading business, and that had "some effect" and delayed offerings. He said IPOs have been pushed back in the calendar. He said equities held up quite "nicely" in October, fixed income "a little quieter" given uncertainty around rates.

09:47 EDT Summit Materials falls -15.7% - Summit Materials is down -15.7%, or -$2.27 to $12.20.

09:47 EDT Bloom Energy falls -20.3% - Bloom Energy is down -20.3%, or -$4.66 to $18.35.

09:47 EDT e.l.f. Beauty rises 19.1% - e.l.f. Beauty is up 19.1%, or $2.12 to $13.22.

09:46 EDT Praxair announces long-term supply agreement with Samsung - Praxair, a wholly-owned subsidiary of Linde plc, announced it has signed a long-term agreement to supply ultra-high purity nitrogen to Samsung's semiconductor facility in Hwaseong, South Korea. This is the fifth plant Praxair will build at this site to help enable Samsung to meet increased global semiconductor demand. Earlier this year, Praxair announced two other long-term agreements with Samsung affiliates in South Korea, one to supply another of Samsung Electronics' semiconductor plants in Pyeongtaek and a second to supply Samsung Electro-Mechanics' facility in Busan.

09:26 EDT Ramaco Resources announces partial structural failure at Elk Creek coal complex - Ramaco Resources announced that on November 5, one of the three raw coal storage silos that feed its Elk Creek plant in West Virginia experienced a partial structural failure, which included the failure of various components internal to the silo. The damaged storage silo holds approximately two thousand raw tons of coal. The other two contiguous silos together hold approximately an additional one thousand five hundred raw tons of coal. Ramaco is in the process of evaluating the structural integrity of the damaged silo, and similar evaluations will be conducted on the other two silos at Elk Creek. All three silos were previously existing on the Elk Creek property when it was acquired by Ramaco in 2012, and were subsequently linked into the newly constructed preparation plant and loadout facility, which was completed in late 2017. There were no personnel related accidents as a result of the structural failure at the silo. Upon confirmation of the failure, Ramaco personnel idled the Elk Creek preparation plant, and placed a safety zone around the areas that could potentially be impacted from a more severe failure. At this early initial stage of review, Ramaco does not have an estimated time frame for the resumption of processing or shipping coal from the Elk Creek infrastructure. All coal mines at Elk Creek will, however, continue to operate as scheduled. Depending on the extent of the damage, Ramaco currently estimates that there is adequate storage area to continue coal production at the mine complex for an extended period of time, likely into December and possibly further. Ramaco has not at this time issued any force majeure notices to its customers, but it is probable that such notices will be issued in the near future. Ramaco believes that it has insurance policies in place to provide adequate financial coverage for the incident, including both business interruption and extra expenses. Additional information relating to the physical condition of the silo assets, insurance coverage and any potential force majeure will be forthcoming as new information is developed. Any such additional new information will be relayed in conjunction with Ramaco's scheduled earnings release on November 7 and its subsequent conference call with investors to be held on November 8.

09:21 EDT Johnson & Johnson announces data from two studies of photochromic contact lenses - Johnson & Johnson Vision announced that data from two new studies on the visual effects of photochromic contact lenses will be presented at the 2018 American Academy of Optometry Annual Meeting in San Antonio. Both studies are among the 'most newsworthy' at the meeting, as selected by the American Academy of Optometry. These are the first scientific presentations focused on photochromic contact lens technology since the lenses received clearance from FDA in April.

09:12 EDT Greenlight's Einhorn says Brighthouse Financial was firm's biggest winner in Q3 - David Einhorn said on Greenlight Capital Re's (GLRE) earnings call that Brighthouse Financial (BHF) was the biggest winner in the quarter, Tesla (TSLA) was the firm's second biggest winner. Einhorn says he believes "this is as good as it gets for" Tesla, as the company is contending with "litany" of issues.

09:11 EDT Arcadia Biosciences enters collaboration with Ardent Mills - Arcadia Biosciences and Ardent Mills announced a collaboration to develop and commercialize innovative wheat varieties. The first project focuses on extending the shelf life and improving the flavor of whole wheat products.

09:07 EDT Carnival announces joint venture with China State Shipbuilding Corporation - Carnival Corporation & plc announced that its cruise joint venture with China State Shipbuilding Corporation, or CSSC, will launch this week under the name CSSC Carnival Cruise Shipping. The new China-based cruise company plans to operate its own fleet to serve Chinese cruise guests by the end of 2019. As part of the news, CSSC Carnival Cruise Shipping Limited announced an agreement to purchase two existing ships from Carnival Corporation's Costa Group, the leading cruise operator in Europe and Asia. The first of these ships, the 85,861-ton, 2,210-passenger Costa Atlantica, is scheduled to be transferred to the new Chinese cruise line by the end of 2019. Costa Atlantica's sister ship, the 2,114-passenger Costa Mediterranea, will be transferred at a date still to be announced. Additionally, CSSC Carnival Cruise Shipping Limited announced it has signed a contract to finalize its previously announced agreement to order two new cruise ships that will be built in China and serve the Chinese cruise market. The two new cruise ships will be constructed by Shanghai Waigaoqiao Shipbuilding, a leading Chinese-owned shipyard in Shanghai, with the first ship expected to be delivered in 2023. The agreement also gives CSSC Carnival Cruise Shipping Limited the option to order four additional China-built cruise ships to serve growing demand from Chinese consumers.

09:03 EDT Dish selects Ericsson for its Narrowband Internet of Things network - DISH Network (DISH) has selected Ericsson (ERIC) to deliver a radio access and core network for DISH's Narrowband Internet of Things network slated for completion in March 2020. Ericsson leveraged its global wireless radio expertise to complete the initial radio frequency design for DISH's nationwide NB-IoT network earlier this year.

09:01 EDT Oncobiologics advances ONS-5010 into wet AMD clinical trial - Oncobiologics announced that it has begun dosing patients in its first clinical trial for ONS-5010, a proprietary ophthalmic bevacizumab product candidate, in patients with wet age related macular degeneration. This first clinical study for ONS-5010, the Company's lead product candidate, is being conducted outside of the United States and is designed to serve as the first of two adequate and well controlled studies for wet AMD. The U.S. portion of the second study is scheduled to begin in early 2019 upon the submission of an investigational new drug application. The Company's wet AMD clinical program was reviewed at a successful end of Phase 2 meeting held with the U.S. FDA conducted earlier in 2018. If the program is successful, it will support the Company's plans to submit for regulatory approval in multiple markets in 2020. The Company is developing ONS-5010 as an innovative therapy and not using the biosimilar drug development pathway.

09:01 EDT Black Knight acquires Ernst Publishing - Black Knight announced that it has acquired Ernst Publishing. Black Knight plans to more tightly integrate the Ernst capabilities into its premier suite of origination solutions, while also making the technology and data available to companies who do not currently use the Black Knight Empower loan origination system, and will continue to work with Ernst's current industry partners and clients.

08:59 EDT CVS Health says 'pleased with solid performance' in Q3 - Says first concept stores to be up and running in early 2019. Says making significant progress on enterprise streamlining efforts through process improvements and technology enhancements. Still expects to generate ~$475M in gross benefits this year; expects savings to ramp in 2019 in line with original expectations. Says for 2019 PBM selling season, to date has completed more than 90% of client renewals, roughly in line with previous years. Says gross wins $2.6B; net wins $875M, up ~$675M from last update. Says Retail pharmacy market share increased ~ 150 bps versus Q3 2017 to all-time high of 25.2%. Says 2019 will be "highly focused" on Aetna integration. Comments from Q3 earnings conference call.

08:51 EDT Deluxe appoints Barry McCarthy as president, CEO - Deluxe Corporation (DLX) announced that Barry McCarthy has been named Deluxe's president, CEO and a member of the Company's Board of Directors, effective November 26, 2018. He joins Deluxe after 14 years at First Data (FDC), where most recently he served as EVP and Head of its Network & Security Solutions business. McCarthy succeeds Lee Schram, who last spring announced his intention to retire from the Company. They will work together closely in the coming weeks to manage a smooth transition of leadership.

08:46 EDT Perspecta awarded $49.8M contract by U.S. AFTAC - Perspecta announced that it has been awarded a prime contract from the U.S. Air Force Technical Applications Center, or AFTAC, to continue work on the Expert Scientific and Analytical Support, or ESAS, II program. This award has a two-year base period, two two-year option periods and a ceiling value of $49.8M. Under the contract, Perspecta will continue to support the research and development of future nuclear detonation systems and other advanced detection technologies to meet AFTAC's evolving operational mission requirements for monitoring treaties and other customer directed technology applications.

08:45 EDT Canadian Pacific announces October shipping record of 2.64MMT of products - Canadian Pacific has broken all-time records for the shipment of grain, moving 2.64 million metric tonnes, or MMT, of Canadian grain and grain products in October. This makes October 2018 CP's biggest month ever for moving Canadian grain, breaking the record from September 2017. During the month of October CP also set a new record for biofuels shipped.

08:42 EDT AirMedia announces transfer agreement with Jiangsu Hong Zhou Investment - AirMedia Group announced that Beijing Linghang Shengshi Advertising one of the variable interest entities of the Company, Herman Guo, the Chairman and CEO of the Company, and Qing Xu, the director and executive president of the Company have entered an equity transfer agreement with Jiangsu Hong Zhou Investment, an independent third party to sell 20.32% equity interest of Airmedia Group for an initial transfer price of RMB580M in cash as adjusted pursuant to the Agreement. Among the total Initial Consideration, the consideration payment of RMB200M will be made in three installments pursuant to the Agreement. Meanwhile, Sellers are obligated to repurchase the equity interests in the Target if the listing/restructuring applications are not duly submitted or the approvals from the competent securities regulatory department are not secured, each within a specified period provided in the Agreement, for the repurchase price as calculated pursuant to the Agreement. In addition, subject to certain conditions provided in the Agreement, the Initial Consideration may be incremented if the Buyer would successfully re-transfer the 20.32% of the equity interest in the Target to a third party above the Initial Consideration or the Buyer makes profit or should have made profit on selling its equity securities in the Target after the completion of listing/restructuring of the Target.

08:36 EDT Theravance Biopharma announces sale of Vibativ to Cumberland Pharmaceuticals - Theravance Biopharma (TBPH) announced the sale of its proprietary antibiotic, Vibativ, to Cumberland Pharmaceuticals (CPIX), a specialty pharmaceutical company focused on the delivery of high-quality prescription brands to improve patient care. Under the terms of the agreement, Cumberland will pay Theravance Biopharma a total of $25M and tiered royalties of up to 20% on future U.S. net product sales. The transaction is expected to close in mid-November, pending satisfaction of customary closing conditions. Theravance Biopharma will provide additional remarks on its previously-scheduled third quarter 2018 earnings call. "This transaction with Cumberland Pharmaceuticals allows Theravance Biopharma to sharpen our focus on our most important strategic priorities, including preparations for the potential launch of YUPELRI in COPD, if approved, plus executing on key pipeline programs. VIBATIV plays an important role in the growing global battle against antibiotic resistance. As we continue our focus on important programs outside of the anti-infectives market, we determined that the product could be best supported by another party. We believe that Cumberland's track record of successfully marketing and selling hospital-based products combined with VIBATIV's existing base of hospital formulary inclusions positions them to drive commercial success for VIBATIV as a flagship product and ensures the important therapeutic benefits of VIBATIV reach as many patients as possible," stated Rick Winningham, chairman and CEO at Theravance.

08:34 EDT Core-Mark increases quarterly dividend 10% to 11c per share - Core-Mark announced that its Board of Directors has approved an 11c cash dividend per common share, or 44c annually, an increase of 10% from the prior dividend. The dividend is payable on December 14, 2018 to stockholders of record as of the close of business on November 20, 2018.

08:34 EDT Cumberland to acquire Vibativ from Theravance Biopharma - Cumberland Pharmaceuticals (CPIX) announced that it has entered into a definitive agreement to acquire Vibativ from Theravance Biopharma (TBPH). Under the terms of the agreement, Cumberland will assume full responsibility for the product including its marketing, distribution, manufacturing and regulatory activities. Cumberland will support Vibativ in the United States through its established hospital sales organization. The company expects to selectively expand its sales force, medical science liaison and corporate teams to ensure the needed support of Vibativ as well as its oncology and acute care brands. The financial terms include a $20M payment to Theravance Biopharma upon closing, a $5M additional payment in early 2019, and tiered royalties of up to 20% on future U.S. net product sales. Cumberland expects that the addition of Vibativ will be accretive to the company's earnings. The transaction is expected to close in mid-November, pending satisfaction of customary closing conditions. Cumberland will provide additional remarks on its upcoming third quarter 2018 earnings call.

08:33 EDT Sparton, Leidos team on Acoustic Device Countermeasure MK5 - Sparton (SPA) announces it has teamed with Leidos Maritime Systems (LDOS) to support the Acoustic Device Countermeasure, or ADC, MK5 program. The MK5 is a Next Generation Countermeasure intended to replace the ADC MK3. The ADC MK 5 is a three-inch diameter expendable device that is submarine launched from internal signal ejectors and is part of a submarine's defense against acoustic-homing torpedoes. On 13 September, 2018, the U.S. Navy announced Leidos had been awarded the contract, valued up to $36.1M, under a competitive solicitation. Sparton will contribute to the contract's scope of work which includes the design, development, fabrication, integration, testing, and Low Rate Initial Production of the U.S. Navy's MK5 program. Sparton will also provide manufacturing services to support system fabrication.

08:32 EDT E.W. Scripps enters into agreement with Massachusetts Mutual Life Insurance - The E.W. Scripps has entered into an agreement with Massachusetts Mutual Life Insurance to purchase a group annuity contract and transfer approximately $50M of the company's pension plan obligations. The transaction will transfer responsibility for the pension benefits to MassMutual for approximately 2,000 Scripps retirees and beneficiaries. MassMutual will begin making benefit payments to the affected plan participants on Jan. 1, 2019. There will be no change to pension plan benefits for plan participants. Through the transaction, Scripps will reduce its pension plan liabilities by approximately $50 million. The purchase of the contract will be funded by assets of the pension plans, and no additional contributions will be required to facilitate the transaction. The transaction is expected to close on Nov. 8. Scripps expects to recognize a one-time non-cash pension settlement charge of between $10M-$12M in the Q4. Impacted retirees and beneficiaries received preliminary notification in August and will be sent additional information later this month.

08:30 EDT Bojangles trading resumes

08:25 EDT Pacific Mercantile Bank provides $7.8M in financing to MonkeySports Capital - Pacific Mercantile Bank, the wholly owned subsidiary of Pacific Mercantile Bancorp announced that it has provided a $7.8M owner-occupied commercial real estate loan to finance the expansion of MonkeySports Capital, a sporting goods retailer. In addition to the financing, MonkeySports utilizes Pacific Mercantile Bank's depository products and treasury management services. MonkeySports is a retailer of ice hockey, lacrosse, baseball and softball equipment. MonkeySports operates 11 retail stores in California, Texas, New Jersey, Massachusetts, Colorado, New Hampshire, Sweden and Canada.

08:23 EDT Ironwood expects to complete separation in 1H19 - "Ironwood carried operating momentum from the first half of 2018 through the third quarter, driven by 12% LINZESS demand growth and further advancement of our five ongoing clinical programs with linaclotide, IW-3718, olinciguat and praliciguat," said Peter Hecht, CEO of Ironwood. "LINZESS is the branded prescription market leader in its class, driven by our productive investments in marketing, personal promotion and payer access. LINZESS is a growth brand with years of expected patent coverage ahead, and we and Allergan are investing in multiple innovative strategies that we believe represent an opportunity to drive significant growth going forward. We also made progress on our planned separation, which we believe will better position both companies to bring new treatment options to patients and unlock value for shareholders. Following the separation, we expect Ironwood will be a profitable, leading U.S. GI company. We expect the R&D Co. to harness its expertise in sGC pharmacology, developing five sGC stimulators tailored for serious and orphan diseases." In May 2018, Ironwood announced its intent to separate into two independent, publicly traded companies. The separation is expected to be completed in the first half of 2019 and is anticipated to be tax-free to Ironwood shareholders. Following the separation, Ironwood expects to be profitable and to focus on building a leading U.S. GI healthcare company. Ironwood intends to leverage its broad capabilities to advance a strong GI portfolio, including LINZESS - the branded prescription market-leading product in its class - and two potentially highly differentiated, late-stage development products in IW-3718 and MD-7246. R&D Co. expects to harness its deep expertise in cyclic guanosine monophosphate pharmacology to advance an innovative sGC stimulator pipeline focused on the treatment of serious and orphan diseases. At its strategic core are expected to be five novel sGC stimulator programs tailored to the tissues most relevant to the diseases they are designed to treat, including olinciguat, praliciguat, IW-6463, and late-stage discovery programs targeting serious liver and lung diseases.

08:21 EDT Ironwood expects total restructuring costs approx. $16M - Ironwood continues to expect in 2018: SG&A expenses to be in the range of $230M to $250M; R&D expenses to be in the range of $160M to $180M; the combined Ironwood and Allergan total marketing and sales expenses for LINZESS to be in the range of $230M to $260M; and, net interest expense to be less than $40M. Ironwood now expects total restructuring costs to be approximately $16M, versus previous guidance of $18M to $21M.

08:16 EDT LogMeln names Arista Networks CFO Ita Brennan to board - LogMeIn, Inc. (LOGM) has named Ita Brennan, CFO of Arista Networks (ANET), to the company's board of directors. Brennan is the second newly appointed director to the LogMeIn Board this year, following the appointment of Sara Andrews, SVP and CISO of PepsiCo (PEP), who was named to the Board in April.

08:12 EDT Alkermes announces presentation of three abstracts of ALKS 4230 study - Alkermes announced the presentation of three abstracts at the Society for Immunotherapy of Cancer's, SITC, 33rd Annual Meeting in Washington, D.C., Nov. 9-11. Initial clinical data from the ongoing monotherapy dose-escalation stage of the phase 1 study for ALKS 4230, the company's immuno-oncology drug candidate, will be presented for the first time. ALKS 4230 is a novel, engineered fusion protein designed to selectively activate tumor-killing immune cells while avoiding the expansion of immunosuppressive cells by preferentially binding to the intermediate-affinity interleukin-2 receptor complex.

08:11 EDT U.S. Gold begins Autumn 2018 drilling program at its Keystone program - U.S. Gold announced the commencement of the Autumn 2018 drilling program at its 20 square mile, Keystone project, in Nevada's Cortez Trend. The program is expected to test several drill targets in areas previously inaccessible with a drill because of permitting limitations. Identification and qualification of these targets has been in progress since the onset of the exploration program almost 3 years ago. This targeting effort has included iterative detailed gravity surveys, detailed geological mapping and associated prospecting, rock sampling and detailed gridded soil surveys, in addition to prior scout hole drilling. 2016-2018 scout-type drill holes, comprised of 22 individual holes drilled from 15 total drill sites, have importantly added to the knowledge of, and geological understandings of the permissive lithologies and favorable stratigraphy of the project. Scout drilling has also encountered thick sections of permissive rock, including Horse Canyon, Wenban, and Roberts Mountains Formations, hosting anomalous to multiple gram gold intervals associated with very anomalous and thick intervals of pathfinder metals.

08:08 EDT Kadmon: KD033 inhibited tumor growth in models in study - Kadmon Holdings announced it will present preclinical data on KD033, its anti-PD-L1/IL-15 fusion protein in development for oncology indications, at the Society for Immunotherapy of Cancer Annual Meeting, taking place November 7-11, 2018, in Washington, D.C. KD033 is a novel immunotherapy designed to stimulate an immune response directed to the tumor microenvironment. Recombinant IL-15 alone, which stimulates cancer-fighting immune effector cells, is not well tolerated when administered systemically. Kadmon has developed a novel approach to overcome this challenge by fusing IL-15 to an anti-PD-L1 antibody to direct IL-15 activity specifically to the tumor microenvironment, promoting efficacy and inducing durable responses while potentially increasing tolerability. New data demonstrated that a single dose of KD033 inhibited tumor growth across multiple in vivo syngeneic tumor models and achieved dose-dependent efficacy in a resistant melanoma syngeneic mouse model. KD033 induced a strong immune memory response with a single treatment, resulting in mice that remained tumor-free following several tumor re-challenges. Furthermore, KD033 in combination with anti-PD1 therapy demonstrated synergistic activity, providing rationale for administering KD033 in combination with other immune checkpoint inhibitors. "Although immunotherapy has been game-changing for the treatment of cancer, many tumors learn to evade current therapies, limiting efficacy and durability of response. New approaches are needed to address relapsed or refractory patients as well as non-responders," said Harlan W. Waksal, M.D., President and CEO at Kadmon. "By directing a potent cancer-fighting response to the tumor site, KD033 has potential to safely overcome resistance and induce long-lasting responses for patients. We look forward to continuing our research on KD033 and initiating our first-in-patient studies in the second half of 2019."

08:06 EDT Verastem announces presentation of preclinical data on duvelisib - Verastem announced a poster presentation of preclinical data by Jonathan Pachter, Ph.D., the company's Chief Scientific Officer, at the Society for Immunotherapy of Cancer's 33rd Annual Meeting being held November 7-11, 2018, in Washington, D.C. "We have assessed the activity of duvelisib, our orally-administered dual inhibitor of PI3K-delta and PI3K-gamma, in combination with either immune checkpoint or co-stimulatory antibodies in syngeneic antitumor models," said Dr. Pachter. "Results to be presented at SITC's 33rd Annual Meeting demonstrated that duvelisib shows strong anti-tumor synergy with PD-1 or OX40 antibodies. As a dual PI3K-delta/gamma inhibitor, duvelisib was found to reduce both immunosuppressive Tregs and myeloid cells in tumors more strongly than PI3K-delta, or PI3K-gamma only inhibitors, suggesting that it could be a highly-differentiated PI3K inhibitor for combination with immuno-oncology therapeutics. These preclinical results support clinical investigation of duvelisib in combination with immunotherapies for treatment of patients with hematological or solid tumor malignancies."

08:05 EDT Essendant, Staples announce extension of tender offer for Essendant shares - Staples and Essendant announced that, pursuant to the Merger Agreement, Egg Merger Sub Inc., affiliates of Staples, have extended the expiration time of the previously announced tender offer for all outstanding shares of Essendant's common stock to 5:00 p.m., New York City time, on November 12, 2018, unless the tender offer is further extended in accordance with the Agreement and Plan of Merger, dated as of September 14, 2018, by and among Essendant, Staples, Egg Parent and Egg Merger Sub. The tender offer was previously scheduled to expire at 5:00 p.m., New York City time, on November 5, 2018. The tender offer is being made pursuant to the Merger Agreement. Egg Merger Sub and Egg Parent expect the tender offer will be consummated promptly following the expiration time, subject to the satisfaction of the remaining closing conditions.

08:03 EDT ConvergeOne to be acquired by CVC for $12.50 per share in $1.8B deal - ConvergeOne Holdings announced that it has entered into a definitive agreement to be acquired by affiliates of CVC Fund VII in an all-cash transaction valued at approximately $1.8B. Subject to customary closing conditions and regulatory approvals, ConvergeOne expects the transaction to close in the fourth quarter of 2018 or the first quarter of 2019. ConvergeOne will maintain its corporate headquarters in Eagan, MN and continue to be led by its current executive team. Pursuant to the terms of the merger agreement, affiliates of CVC will commence a tender offer for all of the outstanding shares of the company in an all-cash transaction valued at $12.50 per share of common stock of the company, representing a 35% premium to the thirty-day VWAP prior to October 25, 2018 and representing over a 56% premium to the closing price on ConvergeOne's debut date on the Nasdaq on February 23. John McKenna Jr., Chairman and CEO of ConvergeOne commented, "Today's announcement is a tremendous accomplishment for ConvergeOne and highlights the continued success of the Company. We are extremely proud of the ConvergeOne team, and we truly appreciate our phenomenal partnership with Clearlake and our other shareholders that has resulted in significant value creation. Our team is thrilled to partner with CVC to execute on the compelling growth opportunities in the rapidly evolving collaboration and technology services market."

08:03 EDT NCR Corp. acquires StopLift Checkout Vision Systems, terms not disclosed - NCR Corporation announced that it has acquired StopLift Checkout Vision Systems, a leader in intelligent computer vision systems, to combat theft in the retail business. Financial terms of the transaction were not disclosed. This transaction reinforces NCR's strategic focus on self-checkout solutions that provide the best possible shopper experience and return on the investment for retailers. NCR will integrate StopLift's Artificial Intelligence capabilities that detect unusual and possibly fraudulent behavior into its retail store transformation solutions. StopLift's loss prevention management features will help NCR address retailers' concerns over shrink. NCR is the global leader in self-checkout technology with more than 250,000 installations worldwide. The two companies anticipate a smooth transition for customers, channel partners and employees.

08:01 EDT ADP raises dividend 25% to 79c - The board of directors of Automatic Data Processing approved a 10c increase in the quarterly cash dividend to an annual rate of $3.16 per share. The increased cash dividend marks the 44th consecutive year in which ADP, a leading provider of Human Capital Management solutions, has raised its quarterly dividend. "The new 79c quarterly dividend represents a 25% increase in the quarterly dividend compared to a year ago, and is a strong signal of the board's confidence in ADP's future and its commitment to shareholder friendly actions," said the company.

07:54 EDT Bojangles trading halted, news pending

07:51 EDT Regulus amends and restructures agreement with Sanofi - Regulus Therapeutics (RGLS) announced that it has amended and restructured its Collaboration and License Agreement with Sanofi (SNY). Under the terms of the Amendment, Regulus has granted Sanofi a worldwide exclusive license to develop and commercialize its investigational drug, targeting miR-21 for all indications, including Alport syndrome. Under the Amendment, Sanofi will assume all future costs and development activities associated with the advancement of RG-012, currently in Phase 2 for Alport syndrome. Under the terms of the Amendment, Regulus is eligible to receive approximately $7M in upfront and material transfer payments. Regulus is also eligible to receive up to $40M in development milestone payments. In addition, Sanofi will reimburse Regulus for certain out-of-pocket transition activities and assume Regulus' upstream license royalty obligations.

07:46 EDT Jacobs Engineering awarded contract extension at Kennedy Space Center - Jacobs Engineering was awarded an extension to the Test and Operations Support Contract at NASA's Kennedy Space Center in Cape Canaveral, Florida. The contract extension is a one-year option with a contract value of $137.5M. NASA estimates the total value of the contract at $818M, which begins in October 2018 and extends the period of performance through September 2019.

07:46 EDT Rosetta Stone names Nick Gaehde, Mathew Hulett as co-presidents - Rosetta Stone announced the appointments of Nick Gaehde and Mathew Hulett as Co-Presidents of Rosetta Stone, Inc. Gaehde and Hulett will continue running the Literacy and Language businesses of Rosetta Stone, respectively, reporting directly to CEO John Hass.

07:44 EDT OpGen completes specimen accrual, testing in Acuitas clinical verification study - OpGen announced it has completed specimen accrual and testing of urine specimens for the clinical verification study with the Acuitas AMR Gene Panel rapid diagnostic test and Acuitas Lighthouse Software, which was initiated in March of this year. The three participating clinical sites were Beth Israel Deaconess Medical Center, Geisinger, and Intermountain Healthcare. The results of the study, which tested 670 remnant urine specimens from patients at increased risk for complicated urinary tract infections, will be summarized and discussed in a peer-reviewed manuscript anticipated to be published in 2019.

07:22 EDT Fastenal reports October net sales up 17.5% to $469.79M - Reports October daily sales up 12.4% to $20.43M.

07:18 EDT Main Street announces new portfolio investment - Main Street Capital announced that it recently led a new portfolio investment to facilitate the management-led buyout of Kickhaefer Manufacturing Companys. Main Street, along with its co-investors, partnered with KMC's management team to facilitate the transaction, with Main Street funding $45.24M in a combination of first-lien, senior secured term debt and a direct majority equity investment. In addition, Main Street and one of its co-investors are providing KMC an undrawn credit facility to support its future organic growth initiatives and working capital needs.

07:15 EDT Carrols Restaurant sees Q4 SSS flat to up 2%

07:14 EDT Protagonist Therapeutics reports results from Phase 1 study of PTG-200 - Protagonist Therapeutics announced top-line results from the Phase 1 study of PTG-200, an oral peptide interleukin-23 receptor antagonist, in 80 normal healthy volunteers. Results of the randomized, double-blind, placebo-controlled, single- and multiple-dose escalation study demonstrated that administration of PTG-200 was well-tolerated. No serious adverse events or dose-limiting toxicities were observed. The pharmacokinetic and pharmacodynamic parameters were consistent with the gastrointestinal-restricted design of PTG-200.

07:13 EDT Armstrong Flooring narrows FY18 adjusted EBITDA view $72M-$78M from $70M-$80M - For the full year 2018, the company now expects adjusted EBITDA to be in the range of $72M to $78M. The adjusted EBITDA outlook assumes sales growth in the low single-digits. The company now expects capital expenditures to be approximately $40M for the full year 2018 while delivering another year of free cash flow in line with recent years.

07:10 EDT Tonix study analysis shows 'meaningful' response to Tonmya in PTSD participants - Tonix Pharmaceuticals presented a poster at CNS Summit 2018 held November 1-4, 2018, in Boca Raton, Fla. A poster, entitled "Time Since Trauma in PTSD: Phase 3 Multi-Center, Double-Blind, Placebo-Controlled Trial of TNX-102 SL, a Sublingual Formulation of Cyclobenzaprine, in Military-Related PTSD" includes results and retrospective analyses from the Phase 3 P301 study. TNX-102 SL, or Tonmya, is being developed for the treatment of posttraumatic stress disorder (PTSD). The poster can be found on the Scientific Presentations page of Tonix's website. The poster presentation reports that a retrospective analysis revealed a treatment effect in participants who experienced trauma less than or equal to nine years prior to screening. For this subgroup, the p-value of the primary endpoint at Week 12, using mixed model repeated measures with multiple imputation, was 0.039. In contrast, there was no benefit relative to placebo in the participants who experienced trauma more than nine years prior to screening. A retrospective analysis of female participants overall, and of military participants with non-combat index traumas experienced less than or equal to nine years from screening, suggests clinically meaningful separation from placebo at Weeks 4 and 12 in these specific subgroups. The female subgroup experienced an 11.5 point improvement in CAPS-5 at Week 4 and 9.1 point improvement at Week 12, while the non-combat participant subgroup experienced a 4.8 point improvement at Week 4 and 4.4 point improvement at Week 12. In addition, the Week 4 assessment of CAPS-5 in the Phase 3 HONOR study showed clinically meaningful improvement at this time point in the entire modified intent-to-treat population. Furthermore, for study participants who experienced trauma less than or equal to nine years prior to screening, all five secondary measures showed a p-value of less than0.05 at the Week 12 endpoint, indicating possible global and functional recovery, and improved sleep quality and mood after 12 weeks of Tonmya treatment compared with placebo. Based on these findings and following a recent Breakthrough Therapy Type B Clinical Guidance meeting with the U.S. FDA, the company plans to incorporate several new design features into the new Phase 3 study, including restricting enrollment of study participants to individuals with PTSD who experienced an index trauma within nine years of screening; enrolling participants who have experienced civilian traumas, in addition to those with military-related traumas; and a CAPS-5 primary endpoint assessed at Week 4 instead of at Week 12.

07:06 EDT Archer Daniels CEO sees 'solid end' to 2018 - "The team delivered another strong quarter, capitalizing on robust global demand with good execution and great utilization of our global footprint," said ADM Chairman and CEO Juan Luciano. "For the last several years, through good conditions and bad, we've remained focused on serving our customers and delivering our strategic plan - optimizing our core, driving efficiencies, and expanding strategically. Now, as we look forward to 2019, we are continuing to enhance our earnings power, both through our growth investments and our Readiness initiative, which is beginning to drive fundamental changes in the way we run our company. Thanks to the team's great work and the growing benefits of our strategic actions, we expect a solid end to 2018, as well as continued momentum for growth in earnings and returns in 2019 and the years to follow."

07:05 EDT Ryder announces opening of facility in St. Charles III - Ryder System announced the grand opening of a new state-of-the-art full-service maintenance facility located in St. Charles, Ill. The new Ryder facility, located at 510 South Tyler Road, St. Charles, IL 60174, will offer customers convenient access to the major trucking highway IL-64, connecting the area to I-355 and I-88.

07:04 EDT Henry Schein sees FY18 one-time restructuring charge 22c-27c - As previously disclosed, Henry Schein is undertaking a comprehensive restructuring plan designed to increase profitability by improving business efficiencies, reducing redundancies, and maximizing the Company's infrastructure. The Company expects to record a one-time restructuring charge in 2018 of between $45 million and $55 million in total on a pretax basis, or $0.22 to $0.27 per diluted share. This restructuring charge primarily includes severance pay, facility closing costs, and outside professional and consulting fees directly related to the restructuring plan. Henry Schein plans to provide details on expected cost savings from this restructuring when the Company provides 2019 financial guidance at a later date.

07:00 EDT Emerson reports Q4 gross margin 42.2%, up 150bps from last year - Q4 Automation Solutions net sales increased 11%. Q4 Commercial & Residential Solutions net sales were up 7%.

06:57 EDT Benefitfocus signs contract with myKlovr for college-planning benefit - MyKlovr has signed a contract with Benefitfocus to offer the first-ever virtual college counseling platform powered by artificial intelligence through Benefitfocus BenefitsPlace, a platform which unifies the entire U.S. benefits industry on a single technology to support consumer health, wellness and lifestyle. Clients of Benefitfocus will now have access to myKlovr's personalized college preparation services, among other benefit products. Based on the myKlovr's growth among consumers this year, it's virtual college counseling solution is now being offered to corporate HR departments and benefits administrators as an innovative tool for attracting and retaining talent. MyKlovr provides personalized, step-by-step college preparation guidance and tools for high school students and their parents. MyKlovr's virtual college counseling will be the first education-planning benefit Benefitfocus will offer under its lifestyle umbrella, which includes services and products designed to reduce stress and anxiety.

06:49 EDT Myers Industries sees FY18 revenue flat to up low-single-digits vs last year - Sees FY18 capital expenditures $6M-$8M; net interest $4M-$6M; depreciation and amortization $26M. The Tax Cuts and Jobs Act will benefit the Company through a decrease in its effective tax rate, which is expected to be approximately 25% compared to approximately 36% in 2017.

06:47 EDT US Foods reports Q3 total case volume down 0.8% - Independent restaurant case volume increased 3.3%. Q3 Adjusted EBITDA increased 6.0% to $283M.

06:41 EDT DPW Holdings to simplify organizational structure - DPW Holdings announced that its board of directors has approved a proposed reorganization of its corporate structure. The reorganization is intended to enhance DPW's ability to reach its objectives, notably its growth strategy, as well as to assist its investors and others to better understand the components and purpose of each subsidiary. DPW Holdings will acquire, grow and spinoff companies in two separate groups: DPW Technology Group and DPW Financial Group. DPW will own 100% of these two groups and anticipates beginning accounting for them separately in 2019: DPW Technology Group will focus on advanced technology, design, power solutions and manufacturing businesses in defense, aerospace, telecom, medical, and textiles. Mr. Ault will serve as the interim CEO, and William B. Horne as the financial executive. DPW Financial Group will focus on lending, cryptocurrency mining, hospitality, and real estate. Darren Magot will serve as CEO and Kenneth S. Cragun as the financial executive.The officers of DPW will remain the same: CEO Milton "Todd" Ault, III, CFO William B. Horne, and CAO Kenneth S. Cragun. DPW anticipates that the corporate restructuring will enable it to leverage more efficiently its sustainable assets, including making additional strategic investments. DPW plans to provide a company update and report third-quarter 2018 financial results in mid-November 2018.

06:38 EDT Premier to acquire Stanson Health in $51.5M deal - Premier signed an agreement to acquire Stanson Health, a software-as-a-service-based provider of clinical decision support tools that are integrated directly into the electronic health record workflow, providing real-time, patient-specific best practices at the point of care. In addition, Stanson is also developing a prior authorization product that, once finalized, is expected to provide near real-time prior authorization decisions for medical and pharmacy benefits. This is expected to save providers and payers time and expense while enhancing patient and provider satisfaction. Premier will utilize existing cash on hand to fund the $51.5M acquisition. The acquisition also provides for an additional earn-out opportunity of up to $15M based on certain product delivery and revenue targets. The acquisition is not expected to materially impact earnings in FY2019, and is expected to be modestly accretive in future years. The transaction is expected to close in Premier's fiscal second quarter ending Dec. 31, 2018, subject to customary closing conditions. The Stanson Health team is expected to continue to operate remotely or out of existing headquarter offices in Southern California. Dr. Weingarten will continue to lead the business unit, reporting to Leigh Anderson, President of Premier's Performance Services segment.

06:31 EDT AmerisourceBergen raises quarterly dividend 5% to 40c per share

06:30 EDT Forterra sees FY18 net loss $25M-$22M - Sees FY18 adjusted EBITDA $166M-$171M.

06:28 EDT Eli Lilly reports Q3 Humalog revenue down 5% to $664.6M - For the third quarter of 2018, Alimta generated worldwide revenue of $520.5 million, which increased 1 percent compared with the third quarter of 2017. For the third quarter of 2018, worldwide Cialis revenue decreased 17 percent to $467.1 million. For the third quarter of 2018, worldwide Humulin revenue increased 7 percent compared with the third quarter of 2017, to $322.1 million. In the third quarter of 2018, worldwide animal health revenue totaled $772.7 million, an increase of 4 percent compared with the third quarter of 2017.

06:26 EDT PQ Group raises FY18 adjusted free cash flow view to $125M-$140M - A yield of ~6%; on track for additional debt paydown by year-end.

06:19 EDT Lexington Realty raises FY18 adjusted FFO view to 93c-95c from 92c-94c - Consensus is for FY18 FFO 93c. Sees FY18 net income attributable to common shareholders per diluted common share 90c-92c.

06:17 EDT Summit Materials cuts FY18 adjusted EBITDA view to $400M-$410M - "For the full-year 2018, the Company has reduced its Adjusted EBITDA guidance from a range of $460 million to $480 million to a range of $400 million to $410 million, including acquisition-related contributions from two transactions that closed since the Company's last update in August 2018. No additional potential acquisitions are included within the Company's full-year 2018 Adjusted EBITDA guidance. For the full-year 2018, the Company has revised its capital expenditure guidance to be in the range of $225 million to $235 million."

06:10 EDT Primoris reports total backlog of $2.7B at September 30 - Compared to $2.6B at December 31, 2017.

06:08 EDT Jeld-Wen sees FY18 revenue up 15%-17% vs last year - The revenue growth outlook includes the impact of lower than anticipated core revenues in the Q3 and Q4. The company's outlook for the FY18 net revenue and adjusted EBITDA remains consistent with the last update provided on October 15. FY18 adjusted EBITDA remains $455M-$470M, compared to 2017 adjusted EBITDA of $437.6M. The midpoint of the outlook assumes a core adjusted EBITDA margin decline of approximately 70 basis points year over year. Sees FY18 capital expenditures $100M-$110M, a reduction of $5M at the midpoint versus previously announced expectations, and an increase compared to 2017 capital expenditures of $63.0M.

06:03 EDT USA Compression sees FY18 net loss ($18.0M)-($8.0M) - USA Compression is updating its FY18 guidance that includes the expected results following the closing of the Transactions on April 2 and the use of the USA Compression Predecessor's results of operations for all periods prior to the closing of the Transactions: Adjusted EBITDA $310.0M-$320.0M; and distributable Cash Flow $170.0M-$180.0M.

05:59 EDT Gol Linhas reports Oct. traffic down 0.9% - GOL's domestic supply and demand decreased 0.1% and 1.9%, respectively. GOL's domestic load factor was 80.0%, a 1.5 p.p. decrease in comparison to October 2017. The volume of departures decreased by 3.1% and seats increased by 1.5% over October 2017. GOL's international supply and demand decreased by 6.8% and 10.3%, respectively, and international load factor was 71.4%, a decrease of 2.7 p.p. in relation to October 2017. GOL's total supply decreased 0.8% due to a 0.9% increase in seats and a 3.4% decrease in departures. GOL's total demand decreased 2.8% in comparison to October 2017 and consolidated load factor was 79.1%.

05:51 EDT Boise Cascade Q3 EPS includes 41c per share in charges - Q3 results include $21.7M of pre-tax losses, or 41c per share after-tax, from a non-cash pension settlement charge and a non-cash impairment loss on assets held for sale in Northeast Oregon. These charges also negatively impacted reported EBITDA and adjusted EBITDA.

05:41 EDT Aegean Marine files voluntary petitions for Chapter 11 - Aegean Marine Petroleum announced that the company and certain of its subsidiaries filed voluntary petitions for relief under Chapter 11 of the US Bankruptcy Code in the Bankruptcy Court for the Southern District of New York. The debtors enter this process with the support of Mercuria Energy Group Limited, a key strategic partner and one of the world's largest independent energy and commodity companies. Mercuria has agreed to provide more than $532 million in postpetition financing to fund the chapter 11 process and the company's working capital needs. It has also agreed to serve as the stalking horse bidder in a sale process designed to optimize the value of the company as a going concern. The company continues to explore value-maximizing alternatives. The debtors have filed a motion with the bankruptcy court seeking to jointly administer all of the debtors' Chapter 11 cases under the caption In re Aegean Marine Petroleum Network Inc., et al. The debtors will continue to operate their businesses as "debtors-in-possession" under the jurisdiction of the bankruptcy court and in accordance with the applicable provisions of the U.S. Bankruptcy Code and orders of the bankruptcy court. The debtors have filed a series of first day motions with the bankruptcy court that seek authorization to continue to conduct their business in the normal course, including in relation to employees, customers and suppliers, among others. The debtors are seeking approval of the Mercuria-led postpetition financing. This financing is designed to ensure the company has adequate working capital to fund the business and continue ordinary course operations during the Chapter 11 Cases and to fund the sale process.

05:38 EDT Pratt & Whitney APS3200 APU selected by Loong Air for new fleet - Pratt & Whitney Canada, a subsidiary of United Technologies, announced that Loong Air has selected the APS3200 auxiliary power unit, or APU, for the airline's order of 29 firm and 5 option Airbus A320 family aircraft. Pratt & Whitney Canada and Loong Air have also signed a long-term comprehensive support agreement to cover the APS3200 APU maintenance. With this APU selection, Loong Air will operate up to 68 Airbus A320 family aircraft with the APS3200 APU.

05:18 EDT CAE signs long-term training agreement with easyJet valued over C$170M - CAE announced at the 2018 European Airline Training Symposium, that it has signed a long-term training contract with easyJet valued at more than C$170M over the next 10 years. Under the agreement, all of easyJet's pilots will train at CAE, which will expand its training network to provide the airline with three new European pilot training locations, equipped with a fleet of CAE's latest XR Series flight simulators. CAE will provide easyJet with state-of-the-art pilot training solutions at training centres located in London Gatwick and Manchester in the UK, as well as Milan, Italy. CAE will build a new state-of-the-art training centre in London-Gatwick with a dedicated space to serve easyJet's training needs and will deploy nine Airbus A320-family full-flight simulators and three flight training devices in the new London Gatwick centre, and two additional training locations in Manchester, UK and Milan, Italy. The centres will be ready for training starting in the second half of 2019.

05:14 EDT j2 Global raises quarterly dividend by 1c to 43.5c per share - j2's board approved a quarterly cash dividend of 43.5c per common share, a 1c, or 2.4% increase versus last quarter's dividend. The dividend will be paid on December 5, to all shareholders of record as of the close of business on November 19.